A Study to Assess the Pharmacokinetics (uptake of drugs by the body), Safety and Tolerability of AZD4831 in Participants with Severe Renal Impairment and Healthy Volunteers

Study identifier:D6580C00009

ClinicalTrials.gov identifier:NCT04949438

EudraCT identifier:2019-003498-25

CTIS identifier:N/A

Study Complete

Official Title

A Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of AZD4831 in Participants with Severe Renal Impairment and Healthy Volunteers

Medical condition

Renal Impairment

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD4831

Sex

All

Actual Enrollment

20

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 21 Jan 2022
Primary Completion Date: 04 Mar 2022
Study Completion Date: 04 Mar 2022

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria